Icosavax, a biopharmaceutical company, creates vaccines for infectious diseases with a focus on respiratory illnesses using its virus-like particle (VLP) platform technology. Its products include vaccines for RSV, hMPV, and SARS-CoV-2, and are currently in different clinical trial phases. Founded in 2017 in Seattle, Icosavax has a mission to save lives with its innovative vaccines.